XPO1 and plasma cell myeloma: The anticancer activity of XPO-1 inhibitors (including selinexor) is p53 mutation independent (65) and is synergistically increased when combined with other chemotherapies and targeted therapies (66–69); the combination with glucocorticoids would intensify the anti-myeloma activity, too (70).